ClinicalTrials.gg
RecruitingNCT07023523Updated Oct 5, 2026

Self-regulation of Real-time fMRI Brain Activity in Chronic Pain

An interventional study of Cognitive Behavioral Therapy and Disease Education in Fibromyalgia, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Oct 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Planned enrollment
234th of 320
36 · median 72
Started
2025
with 11 others
No phase
167 of 369
34 open now
Primary completion
2027-02
later than 23 of 62 live
Registered
345th of 369
by date

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 234th largest by planned enrollment of the 320 interventional ones that give a count, is one of 12 that started in 2025, is one of 167 with no phase, reaches primary completion later than 23 of the 62 other live ones, and was the 345th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

This study aims to explore the usefulness of self-regulation of brain activity in patients with fibromyalgia. Patients will use real-time functional magnetic resonance imaging (fMRI) neurofeedback to observe and regulate their own brain activity while applying mental strategies to reduce fibromyalgia pain. The study consists of 2 magnetic resonance imaging (MRI) visits that involve brain neuroimaging for fMRI neurofeedback tasks, as well as 8 weekly intervention sessions with a pain psychologist. Patients will be randomized to either Cognitive Behavioral Therapy (CBT) or Fibromyalgia Education groups.

Read the detailed description

Pain catastrophizing-a negative cognitive and emotional process that involves helplessness, rumination, and magnification of pain complaints-is the most consistent psychosocial factor predicting deleterious outcomes in chronic musculoskeletal pain, including fibromyalgia. We will use real-time functional magnetic resonance imaging (fMRI) neurofeedback as a research probe to elucidate the neurological mechanisms underlying self-regulation of pain catastrophizing in individuals with fibromyalgia.

Investigators will recruit patients diagnosed with fibromyalgia. In the baseline magnetic resonance imaging (MRI) visit, participants will complete a fMRI neurofeedback session inside an MRI scanner. Prior to entering the scanner, participants will complete several questionnaires and discuss with the research team the self-regulation strategies they plan to use during the neurofeedback task to modulate fibromyalgia pain. For the neurofeedback, participants will be presented with a visual representation of their brain activity performance so that they can maintain or update their strategy throughout the run. As part of the baseline visit, investigators will also apply moderate pressure pain to the patient's leg in the scanner to see how their brain responds to the experimental pain stimulation.

After the baseline visit, participants will be randomly assigned into the Cognitive Behavioral Therapy (CBT) or Fibromyalgia Education groups, and they will then attend 8 weekly intervention sessions with a pain psychologist. During the post-intervention MRI visit, participants will complete the same questionnaires and tasks performed at the baseline visit to assess changes in neural mechanisms underlying the self-regulation of fibromyalgia pain and the experience of experimental pain. All outcome measures will be assessed at both baseline and post-intervention visits.

03

Conditions studied

  • Fibromyalgia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-65
  2. Meet the Wolfe et al 2011 research criteria for fibromyalgia for at least one year
  3. On stable doses of medication prior to entering the study and agree not to change medications or dosages (or CAM treatments) during the trial
  4. Baseline pain intensity of at least 4/10 on average and pain report for at least 50% of days
  5. Able to provide written consent and fluent in English

Exclusion criteria

Exclusion Criteria:

  1. Comorbid acute pain condition
  2. Comorbid chronic pain condition that is rated by the subject as more painful than fibromyalgia
  3. Stimulant medications for the fatigue associated with sleep apnea or shift work (e.g., modafinil),
  4. Pregnant or nursing
  5. Any psychiatric disorder involving a history of psychosis (e. g schizophrenia, severe personality disorders)
  6. History of anxiety disorders or significant anxiety symptoms interfering with fMRI procedures (e.g., panic)
  7. to MRI (e.g., implanted ferrous metal)
  8. History of significant head injury (e.g., with substantial loss of consciousness)
  9. Psychiatric hospitalization in the past 6 months
  10. Other contraindications to MRI
  11. Participating in other therapeutic trials
  12. Active suicidal ideation
  13. Documented peripheral neuropathy of known cause (e.g diabetic neuropathy, chemotherapy-induced neuropathy, guillain-barre)
  14. Routine or daily use of narcotics or substances of abuse
  15. or inflammatory disease (RA, SLE, IBD) that causes pain
  16. Lower Limb Vascular Surgery or Current Lower Limb Vascular Dysfunction
  17. Any impairment, activity or situation that in the judgment of the Study Coordinator or Principal Investigator that would prevent satisfactory completion of the study protocol. This includes unreliable, or inconsistent pain scores as deemed by the principal investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Cognitive Behavioral Therapy

    8 individual weekly visits with a psychologist for pain-related CBT.

    Behavioral: Cognitive Behavioral Therapy

  • Active comparator
    Disease Education

    8 individual weekly visits with a psychologist for fibromyalgia education (this is an active comparator arm, matched for provider contact).

    Behavioral: Disease Education

Interventions

  • BehavioralCognitive Behavioral Therapy

    Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.

  • BehavioralDisease Education

    Providing information about fibromyalgia, including its potential causes and management approaches.

06

What researchers measure

Primary outcomes

  1. Changes in brain activity in pain-associated regions such as vPCC/RSC

    Changes in brain activity in pain-associated regions such as vPCC (ventral posterior cingulate cortex)/RSC (retrosplenial cortex), quantified as z-scores, during the self-regulation period of the MRI scan.

    Time frame: Brain activity data will be collected at baseline and at post-treatment, spanning approximately 4 months.

Secondary outcomes

  1. Pain Catastrophizing Scale (PCS)

    Pain catastrophizing will be assessed with the Pain Catastrophizing Scale (PCS). Pain Catastrophizing Scale (PCS) is a validated survey instrument that assesses the extent of catastrophizing thinking related to pain. Pain catastrophizing is assessed on a scale from 0 to 52, with higher scores indicating a higher levels of catastrophizing.

    Time frame: PCS will be assessed at baseline and at post-treatment, spanning approximately 4 months.

  2. Brief Pain Inventory (BPI)

    Brief Pain Inventory (BPI) is a validated questionnaire designed to assess the severity and interference of pain experienced. Pain severity is assessed on a scale from 0 (no pain) to 10 (severe pain). Pain interference is assessed on a scale from 0 (no interference) to 10 (severe interference).

    Time frame: BPI will be assessed at baseline and at post-treatment, spanning approximately 4 months.

Other outcomes

  1. Self-regulation performance

    During each real-time fMRI self-regulation trial, patients will receive visual feedback of their modulated brain activity, and neurofeedback performance will be measured by their ability to successfully modulate the visual feedback indicator (i.e., increasing/decreasing it as instructed). Changes in performance scores between baseline and post-treatment will be calculated.

    Time frame: Self-regulation performance will be assessed at baseline and at post-treatment, spanning approximately 4 months.

  2. Chronic Pain Self-Efficacy Score (CPSS)

    Chronic Pain Self-Efficacy Score (CPSS) is a validated survey instrument that assesses an individual's beliefs and confident in their ability to manage and cope with chronic pain. Each item on the instrument is scored on a 10-point Likert Scale, from 10 (very uncertain) to 100 (very certain). Average subscale scores are calculated for each domain: self-efficacy for pain management (PSE), self-efficacy for coping with symptoms (CSE), and self-efficacy for physical function (FSE).

    Time frame: CPSS will be assessed at baseline and at post-treatment, spanning approximately 4 months.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 16 months is close to that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Jul 2026 → Feb 2027 and completion Jul 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2025
First posted
Jun 17, 2025
StartActual
Oct 31, 2025
Primary completionEst.
Feb 2027was Jul 2026
CompletionEst.
Feb 2027was Jul 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Feb 2027
Oct 5, 2026
Study completion
Jul 2026→Feb 2027
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Primary completion Jul 2026→Feb 2027
    Study completion Jul 2026→Feb 2027
    + 3 other changes: identifiers, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07023523
Responsible party
Robert Edwards (Professor of Anaesthesia, Brigham and Women's Hospital) — Principal investigator
First posted
Jun 17, 2025
Start date
Oct 31, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Soobin Choi, schoi38@mgb.org
Contact
schoi38@mgb.org
617-952-6742
Jeungchan Lee, PhD
principal investigator · Spaulding Rehabilitation Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion